THE SRC-INHIBITORY PEPTIDE TAT-CX43266-283 TARGETS TUMOR-INITIATING NEURAL STEM CELLS IN PRECLINICAL MODELS OF GLIOBLASTOMA

• Andrea Álvarez-Vázquez,
• Josephine Volovetz,
• Laura San-Segundo,
• Pilar Cerveró-García,
• Raquel Flores-Hernández,
• Berta Segura-Collar,
• Pilar Sánchez-Gómez,
• Steven Pollard,
• Justin Lathia,
• Arantxa Tabernero

Affiliations

Andrea Álvarez-Vázquez

University of Salamanca, Neuroscience Institute Of Castilla Y León (incyl), Institute For Biomedical Research Of Salamanca (ibsal), Salamanca, Spain

Josephine Volovetz

Lerner Research Institute, Cleveland Clinic, Department Of Cardiovascular & Metabolic Sciences, Cleveland, United States of America; Case Western Reserve University, Cleveland Clinic Lerner College Of Medicine, Cleveland, United States of America

Laura San-Segundo

Institute for Biomedical Research of Salamanca (IBSAL), Centre For Cancer Research-ibmcc (csic), Salamanca, Spain

Pilar Cerveró-García

University of Salamanca, Neuroscience Institute Of Castilla Y León (incyl), Institute For Biomedical Research Of Salamanca (ibsal), Salamanca, Spain

Raquel Flores-Hernández

University of Salamanca, Neuroscience Institute Of Castilla Y León (incyl), Institute For Biomedical Research Of Salamanca (ibsal), Salamanca, Spain

Berta Segura-Collar

Carlos III Health Institute, Neuro-oncology Unit, Madrid, Spain

Pilar Sánchez-Gómez

Carlos III Health Institute, Neuro-oncology Unit, Madrid, Spain

Steven Pollard

University of Edinburgh, Centre For Regenerative Medicine, Institute For Regeneration And Repair, Edinburgh, United Kingdom

Justin Lathia

Lerner Research Institute, Cleveland Clinic, Department Of Cardiovascular & Metabolic Sciences, Cleveland, United States of America; Case Western Reserve University, Cleveland Clinic Lerner College Of Medicine, Cleveland, United States of America

Arantxa Tabernero

University of Salamanca, Neuroscience Institute Of Castilla Y León (incyl), Institute For Biomedical Research Of Salamanca (ibsal), Salamanca, Spain